ADAM CASILLAS: Open Payments
NPI 1083918346 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$377 in 22 payments from 8 companies in 2025. Trend: 2023 $1,385 · 2024 $600 · 2025 $377
Food & beverage: $377
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $171 |
| Amgen Inc. | 3 | $63 |
| ViiV Healthcare Company | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Abbott Laboratories | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| PFIZER INC. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: VRAYLAR, OTEZLA, APRETUDE, QULIPTA, CAPLYTA, UBRELVY, FREESTYLE LIBRE 3, ZEPBOUND.
Industry payments across TX — which companies pay providers there.
